NEW YORK (GenomeWeb News) – Agilent Technologies reported after the close of the market on Wednesday that revenues during its fiscal third quarter inched up 2 percent year over year as the company missed the average analyst estimate on the top and bottom line.

For the three months ended July 31, revenues totaled $1.72 billion, compared to $1.69 billion for the third quarter a year ago. The company fell short of the average analyst estimate of $1.79 billion.

Orders during the quarter were down 2 percent to $1.66 billion from $1.69 billion a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.